Buy Evkeeza (evinacumab) Online

Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.

Evkeeza is used in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare, inherited form of high cholesterol that can lead to serious health problems, including heart disease and stroke, at a young age.

Evkeeza works by blocking the activity of ANGPTL3. ANGPTL3 inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), two enzymes that break down fats in the blood. By blocking ANGPTL3, Evkeeza increases the activity of LPL and EL, which leads to a reduction in LDL-C levels.

Evkeeza is administered as a subcutaneous injection once every four weeks. The dosage is individualized based on the patient’s weight and response to treatment.

In clinical trials, Evkeeza was shown to be very effective in lowering LDL-C levels in patients with HoFH. In one study, Evkeeza reduced LDL-C levels by an average of 48% after 12 weeks of treatment. Evkeeza was also well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.

Evkeeza is a significant advance in the treatment of HoFH. It is the first effective treatment for this condition that is not associated with serious side effects. Evkeeza can help patients with HoFH to reduce their risk of heart disease, stroke, and other serious health problems.

Here are some additional details about Evkeeza:

• It is a first-of-its-kind treatment for HoFH.
• It is used in combination with other cholesterol-lowering medicines.
• It is administered as a subcutaneous injection once every four weeks.
• It has been shown to be very effective in lowering LDL-C levels in patients with HoFH.
• It is well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.

Evkeeza is a promising new treatment for HoFH that can help patients to reduce their risk of heart disease, stroke, and other serious health problems.